Theranostics Market

Report Code PH 8913
Published in Jan, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations - Global Forecast to 2028

Overview

The global theranostics market in terms of revenue was estimated to be worth $2.1 Billion in 2023 and is poised to reach $4.3 Billion by 2028, growing at a CAGR of 15.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increasing establishment of hospitals, rising focus on targeted therapies, and introduction of novel theranostic approaches are expected to drive the market during the forecast period. Introduction of artificial intelligence (AI) helps to improve the diagnostic accuracy. Recent FDA approvals increases the awareness and supports rising adoption of theranostics.

Attractive Opportunities in the Theranostics Market

NORTH AMERICA

North America is expected to be the largest regional market due to the rising adoption of theranostics and increasing incidence of cancer.

Market growth can be attributed to factors such as the rising prevalence of target diseases, increasing use of radiopharmaceuticals, and growing focus on precision medicine.

Rising installations and growing awareness in emerging countries to provide lucrative opportunities for market players.

The European theranostics market is expected to reach USD 1.1 billion by 2028, growing at CAGR of 13.8% during the forecast period.

Emerging economies such as China and India are expected to offer opportunities for the growth of the theranostics market.

Global Theranostics Market Dynamics

DRIVER: Rising focus on precision medicine to propel the market

Precision medicine or personalized medicine involves the targeted approach for a patient by considering the difference in the genes and other factors such as lifestyles and environments. Specific characteristics of a patient are analyzed tailored for innovative approach to medical treatment. The treatment or therapy designed for the patient by considering the molecular and cellular profile results in effective prevention, diagnosis, improved outcomes, and reduced side effects.Theranostics, a combination of diagnostics and therapy, emphasizes individualized and targeted therapies. Theranostics and precision medicine proves to be helpful with the better management of patients suffering through cancer. Specific biomarkers are identified to know the patient’s response to the treatment. This helps healthcare professionals with decisions such as drug selection that leads to higher treatment success rates. Identification of molecular basis of the disease in precision medicine is supported by theranostics. Theranostics provides diagnostic tools that helps with identifying the patients that are best suited for the treatment. Hence, rising incidents of cancer and increasing focus on presonlized treatment is anticipated to propel the market in future.

RESTRAINT: Short half-life of radiopharmaceuticals

The expiry of a radiopharmaceutical primarily depends on the half-life of the radioisotope and the content of the radionuclide. For example, the radioactivity of F-18 decreases if not used within 110 minutes, while the radioactivity of C-11 decreases within 20 minutes. Whereas the radioactivity of Tc-99m is reduced after six hours, while I-123 and In-111 isotopes should be utilized within 13 and 67 hours, respectively. The non-utilization of radioisotopes within the prescribed shelf life causes radiation and chemical decomposition. This leads to reduction in the radiochemical purity to an unacceptable form, which may prove fatal during diagnosis and therapy. As a result, the geographic locations of the production site and usage site of radioisotopes have to be proximate. This increases the investment required for the establishment of production facilities. Additionally, the shorter half-life of radiopharmaceuticals creates a need for in-house radiopharmaceutical production in cyclotrons/generators within hospital premises, further increasing the capital expenditure for hospitals.

 

OPPORTUNITY: Growth opportunities in emerging countries

Developing economies such as offer growth opportunities for the major players in the market. Although the cost factor is a concern in these developing countries, their huge population base—especially in India and China—offers a sustainable market for theranostics.The high incidence of chronic diseases such as cancer, strokes, and neurological and cardiovascular diseases, as well as the high death rates in these countries, have increased the need for early detection. According to a GLOBOCAN 2020 report, the number of new cancer cases diagnosed in 2020 was 19.3 million, and almost 10.0 million died due to cancer.Key market players are adopting various growth strategies to strengthen their foothold in this region. For instance, in August 2019, Eckert & Ziegler (Germany) initiated a joint venture with Chengdu New Radiomedicine Technology Co., Ltd. (China) to set up a new production facility for radiopharmaceuticals used in the treatment of hepatocellular carcinomas in China. According to an article published in the European Journal of Nuclear Medicine and Molecular Imaging 2022, by 2025, about 50 new centralized radiopharmacies will be built across China, and the availability and accessibility of radiopharmaceuticals will be significantly improved by then.All these factors are expected to offer growth opportunities for players operating in the market.

CHALLENGE: Shortage of trained professionals

The rising cost of prescription drugs and a sharp decline in the proposed budget allocations for Health and Human Services in the US have significantly reduced hospital budgets. A study by the American Hospital Association estimates that federal payment cuts to hospitals would amount to USD 218 billion by 2028, forcing hospitals to allocate smaller budgets annually.Healthcare facilities that purchase expensive equipment such as cyclotron or nuclear reactors and radiotracers often depend on third-party payers (such as Medicare, Medicaid, or private health insurance plans) to avail reimbursements for costs incurred in diagnostic, screening, and therapeutic procedures performed with these devices. However, continuous cuts in the reimbursement and the increasing cost of radiotracers due to their limited availability prevent imaging centers from investing in these modalities.Moreover, owing to the high cost of the equipment, most hospitals in developing countries are unable to afford this highly sophisticated technology. Due to the high cost of these systems and financial limitations, healthcare facilities such as small hospitals and cancer care centers are reluctant to invest in this equipment. This will force them to focus on lower-priced alternatives, such as refurbished devices or upgrades of existing devices.

Global Theranostics Market Ecosystem Analysis

By product, the diagnostic imaging segment of theranostics industry accounted for the largest share in 2022. Based on product, the theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software and services. In 2022, the diagnostic imaging segment accounted for the largest market share. The rising use of advanced instruments supporting accurate diagnosis and availability of systems with better sensitivity is driving the segment growth.

 

By application, the prostate cancer segment of theranostics industry to register significant growth in the near future.

Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. Prostate cancer segment to register the highest growth rate during the forecast period. The major factors responsible for the highest growth rate of this segment are the rising incidence of prostate cancer and increasing investments and funds related to cancer.

By end user, the hospitals segment of theranostics industry accounted for the largest share in 2022.

Based on end user, the global theranostics market is segmented into hospitals and cancer care centers, theranostics centers, and research and academic centers. In 2022, hospitals and cancer care segment accounted for the largest market share. The highest share of this segment is attributed to the rising aoption of theranostic treatment at the hospitals for and increasing awareness regarding benefits of the treamtment. This is primarily attributed to the recent approvals and the rising adoption advanced diagnostic imaging systems with improved features in hospitals supporting patient care.

NORTH AMERICA Region Holds the Largest Share of the Theranostics Market.

North America accounted for the largest share of the Theranostics Market in 2022. Factors such as rising cancer incidence and rising number of investments supporting increasing adoption of theranostics is driving the market growth. Rapid growth in the old age population in the region and establishment of the theransotics centers are supporting the growth of the market.

Recent Developments of Theranostics Market industry

  • Advanced Accelerator Applications (France) received FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan). Pluvicto is a targeted radioligand therapy for patients with prostate cancer with a therapeutic radioisotope. Bayer AG (Germany) and the Broad Institute of MIT and Harvard (US) extended their long term collaboration for the advancement of new therapeutic approaches in cancer.
  • GE Healthcare collaborated with the Mayo Clinic (US) for innovation in research and product development. The collaboration aims to have the technology for clinicians for the precise diagnosis and approaches to theranostics and medical imaging.

Key Market Players

Want to explore hidden markets that can drive new revenue in Theranostics Market?

Scope of the Report

Report Attribute Details
Market Revenue in 2023 $2.1 Billion
Projected Revenue by 2028 $4.3 Billion
Revenue Rate Poised to Grow at a CAGR of 15.5%
Market Driver Rising focus on precision medicine to propel the market
Market Opportunity Growth opportunities in emerging countries

Key Questions Addressed by the Report

What is the projected market revenue value of the global theranostics market?
The global theranostics market boasts a total revenue value of $4.3 Billion by 2028.
What is the estimated growth rate (CAGR) of the global theranostics market?
The global theranostics market has an estimated compound annual growth rate (CAGR) of 15.5% and a revenue size in the region of $2.1 Billion in 2023.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Theranostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
19
RESEARCH METHODOLOGY
23
EXECUTIVE SUMMARY
36
PREMIUM INSIGHTS
39
MARKET OVERVIEW
43
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Growing geriatric population and rising prevalence of target diseases
    - Increasing use of radiopharmaceuticals in neurological applications
    - Growing focus on precision medicine
    RESTRAINTS
    - Short half-life of radiopharmaceuticals
    - Unfavorable healthcare reimbursement scenario
    OPPORTUNITIES
    - Growth opportunities in emerging economies
    - Rising number of R&D programs for radiopharmaceuticals
    CHALLENGES
    - Hospital budget cuts and high equipment costs
  • 5.3 PRICING ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM/MARKET MAP
  • 5.6 SUPPLY CHAIN ANALYSIS
    PROMINENT COMPANIES
    SMALL & MEDIUM-SIZED ENTERPRISES
    END USERS
  • 5.7 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.8 REGULATORY LANDSCAPE
    NORTH AMERICA
    - US
    - Canada
    EUROPE
    ASIA PACIFIC
    - Australia
    - India
    - China
    REST OF THE WORLD
    - Turkey
    - UAE
    - South Africa
  • 5.9 TIMELINE FOR THERANOSTICS MARKET
  • 5.10 REIMBURSEMENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    TRADE ANALYSIS FOR THERANOSTICS MARKET
  • 5.12 PATENT ANALYSIS
  • 5.13 CASE STUDY ANALYSIS
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS
    IMPACT ANALYSIS OF KEY BUYING CRITERIA
  • 5.15 KEY CONFERENCES & EVENTS
  • 5.16 CLINICAL RESEARCH DATA FOR THERANOSTICS MARKET
THERANOSTICS MARKET, BY PRODUCT
70
  • 6.1 INTRODUCTION
  • 6.2 DIAGNOSTIC IMAGING
    EASY ANALYSIS OF DISEASE CONDITIONS AND ACCURATE THERAPIES TO DRIVE MARKET
  • 6.3 RADIOPHARMACEUTICALS
    LUTETIUM-177
    - Increasing incidence of neuroendocrine cancer to boost segment
    - Samarium-153
    - Rising incidence of bone metastasis to drive segment growth
    - Radium-223
    - Iodine-131
    - Yttrium-90
    - Other radiopharmaceuticals
  • 6.4 IVD/BIOMARKER SCREENING
    RISING ADOPTION OF THERANOSTICS TREATMENT TO SUPPORT MARKET GROWTH
  • 6.5 SOFTWARE & SERVICES
    RISING USE OF NOVEL SOFTWARE AND INCREASING DEMAND FOR IMAGING SERVICES TO PROPEL MARKET
THERANOSTICS MARKET, BY APPLICATION
80
  • 7.1 INTRODUCTION
  • 7.2 PROSTATE CANCER
    RISING INCIDENCE OF PROSTATE CANCER AMONG MEN TO FUEL MARKET
  • 7.3 BONE METASTASIS
    INTRODUCTION OF NOVEL MEDICAL THERAPIES TO DRIVE MARKET
  • 7.4 OTHER CANCERS
  • 7.5 OTHER APPLICATIONS
THERANOSTICS MARKET, BY END USER
85
  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS AND CANCER CARE CENTERS
    RISING TREND OF MODERNIZING IMAGING WORKFLOW SYSTEMS TO DRIVE MARKET
  • 8.3 THERANOSTICS CENTERS
    GROWING FOCUS ON TARGETED THERAPIES AND RISING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET
  • 8.4 RESEARCH AND ACADEMIC CENTERS
    INCREASING COLLABORATIONS BETWEEN THERANOSTICS COMPANIES AND ACADEMIA TO SUPPORT MARKET GROWTH
THERANOSTICS MARKET, BY REGION
90
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
  • 9.3 NORTH AMERICA: RECESSION IMPACT
    US
    - US to dominate North American theranostics market during forecast period
    CANADA
    - Rising geriatric population and increasing number of initiatives for medical isotope development to drive market
  • 9.4 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Well-established healthcare system and increased geriatric population to drive market
    UK
    - Increasing government funding in diagnostic imaging to support market growth
    FRANCE
    - Favorable government initiatives and high incidence of cancer to propel market
    REST OF EUROPE
  • 9.5 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    JAPAN
    - Established nuclear medicine infrastructure and better accessibility of healthcare services to drive market
    CHINA
    - Increasing number of government initiatives and growing geriatric population to drive market
    INDIA
    - Rising number of nuclear medicine facilities and increasing incidence of chronic diseases to propel market
    REST OF ASIA PACIFIC
  • 9.6 REST OF THE WORLD
    REST OF THE WORLD: RECESSION IMPACT
COMPETITIVE LANDSCAPE
125
  • 10.1 OVERVIEW
  • 10.2 KEY STRATEGIES/RIGHT TO WIN
  • 10.3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THERANOSTICS MARKET
  • 10.4 REVENUE SHARE ANALYSIS
  • 10.5 MARKET SHARE ANALYSIS
  • 10.6 COMPANY EVALUATION MATRIX
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT
  • 10.7 START-UP/SME EVALUATION MATRIX
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING
  • 10.8 COMPETITIVE SCENARIOS & TRENDS
COMPANY PROFILES
136
  • 11.1 KEY PLAYERS
    ADVANCED ACCELERATOR APPLICATIONS
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    BAYER AG
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    GE HEALTHCARE
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    CARDINAL HEALTH
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    PHILIPS HEALTHCARE
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    CANON INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    CURIUM
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    LANTHEUS
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    NORTHSTAR MEDICAL RADIOISOTOPES
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    ECKERT & ZIEGLER
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    PHARMALOGIC
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    ECZACIBASI-MONROL
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    ACROTECH BIOPHARMA, INC.
    - Business overview
    - Products/Services/Solutions offered
  • 11.2 OTHER PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    GLOBAL MEDICAL SOLUTIONS
    SHINE TECHNOLOGIES, LLC
    ISOTOPIA MOLECULAR IMAGING LTD.
    INSTITUTE OF ISOTOPES
    CHINA ISOTOPE & RADIATION CORPORATION
    YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
    ATOMVIE
    ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
    TELIX PHARMACEUTICALS LIMITED
    BLUE EARTH DIAGNOSTICS
    SOFIE BIOSCIENCES
    THERAGNOSTICS
APPENDIX
186
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 RISK ASSESSMENT: THERANOSTICS MARKET
  • TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS
  • TABLE 3 AVERAGE COST FOR THERANOSTICS TREATMENT, BY REGION
  • TABLE 4 PORTER’S FIVE FORCES ANALYSIS: THERANOSTICS MARKET
  • TABLE 5 REGULATORY AGENCIES AND GUIDELINES
  • TABLE 6 MEDICAL REIMBURSEMENT CODES FOR THERANOSTICS IN US, 2022
  • TABLE 7 IMPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND)
  • TABLE 8 EXPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND)
  • TABLE 9 CASE STUDY 1: LUTETIUM-177-PSMA-617 FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
  • TABLE 10 KEY STAKEHOLDERS AND THEIR REQUIREMENTS
  • TABLE 11 IMPACT OF KEY STAKEHOLDERS ON BUYING CRITERIA
  • TABLE 12 LIST OF KEY CONFERENCES & EVENTS, 2023–2024
  • TABLE 13 THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 14 THERANOSTICS MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 15 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 16 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 17 LUTETIUM-177 MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 18 SAMARIUM-153 MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 19 RADIUM-223 MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 20 IODINE-131 MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 21 YTTRIUM-90 MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 22 OTHER RADIOPHARMACEUTICALS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 23 THERANOSTICS MARKET FOR IVD/BIOMARKER SCREENING, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 24 THERANOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 25 THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 26 THERANOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 27 THERANOSTICS MARKET FOR BONE METASTASIS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 28 THERANOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 29 THERANOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 30 THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 31 THERANOSTICS MARKET FOR HOSPITALS AND CANCER CARE CENTERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 32 THERANOSTICS MARKET FOR THERANOSTICS CENTERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 33 THERANOSTICS MARKET FOR RESEARCH AND ACADEMIC CENTERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 34 THERANOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 35 NORTH AMERICA: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 36 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 37 NORTH AMERICA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 38 NORTH AMERICA: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 39 NORTH AMERICA: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 40 US: KEY MACROINDICATORS
  • TABLE 41 US: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 42 US: THERANOSTICS MARKET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 43 CANADA: KEY MACROINDICATORS
  • TABLE 44 CANADA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 45 CANADA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 46 EUROPE: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 47 EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 48 EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 49 EUROPE: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 50 EUROPE: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 51 GERMANY: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 52 GERMANY: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 53 UK: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 54 UK: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 55 FRANCE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 56 FRANCE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 57 REST OF EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 58 REST OF EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 64 JAPAN: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 65 JAPAN: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 66 CHINA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 67 CHINA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 68 INDIA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 69 INDIA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 70 REST OF ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 71 REST OF ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 72 REST OF THE WORLD: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 73 REST OF THE WORLD: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 74 REST OF THE WORLD: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 75 REST OF THE WORLD: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 76 DEGREE OF COMPETITION IN THERANOSTICS MARKET
  • TABLE 77 PRODUCT AND REGIONAL FOOTPRINT
  • TABLE 78 DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 81 ADVANCED ACCELERATOR APPLICATIONS: COMPANY OVERVIEW
  • TABLE 82 BAYER AG: COMPANY OVERVIEW
  • TABLE 83 GE HEALTHCARE: COMPANY OVERVIEW
  • TABLE 84 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 85 CARDINAL HEALTH: COMPANY OVERVIEW
  • TABLE 86 PHILIPS HEALTHCARE: COMPANY OVERVIEW
  • TABLE 87 CANON INC.: COMPANY OVERVIEW
  • TABLE 88 CURIUM: COMPANY OVERVIEW
  • TABLE 89 LANTHEUS: COMPANY OVERVIEW
  • TABLE 90 NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY OVERVIEW
  • TABLE 91 ECKERT & ZIEGLER: COMPANY OVERVIEW
  • TABLE 92 PHARMALOGIC: COMPANY OVERVIEW
  • TABLE 93 ECZACIBASI-MONROL: COMPANY OVERVIEW
  • TABLE 94 ACROTECH BIOPHARMA, INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN METHODOLOGY
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 5 COMPANY REVENUE ESTIMATION
  • FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF BAYER AG
  • FIGURE 7 BOTTOM-UP APPROACH: THERANOSTICS MARKET
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 THERANOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
  • FIGURE 11 THERANOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
  • FIGURE 12 THERANOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
  • FIGURE 13 REGIONAL SNAPSHOT OF THERANOSTICS MARKET
  • FIGURE 14 RISING PREVALENCE OF CANCER AND GROWING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET
  • FIGURE 15 RADIOPHARMACEUTICALS TO COMMAND LARGEST MARKET SHARE IN NORTH AMERICAN THERANOSTICS MARKET DURING FORECAST PERIOD
  • FIGURE 16 PROSTATE CANCER TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
  • FIGURE 17 HOSPITALS AND CANCER CARE CENTERS TO COMMAND LARGEST SHARE IN ASIA PACIFIC MARKET DURING FORECAST PERIOD
  • FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD
  • FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: THERANOSTICS MARKET
  • FIGURE 20 AVERAGE SELLING PRICE FOR RADIOPHARMACEUTICALS
  • FIGURE 21 VALUE CHAIN ANALYSIS: THERANOSTICS MARKET
  • FIGURE 22 SUPPLY CHAIN ANALYSIS: THERANOSTICS MARKET
  • FIGURE 23 TOP 10 PATENT APPLICANTS FOR THERANOSTICS (JANUARY 2012–DECEMBER 2022)
  • FIGURE 24 NORTH AMERICA: CANCER PREVALENCE, 2012–2020
  • FIGURE 25 NORTH AMERICA: THERANOSTICS MARKET SNAPSHOT (2022)
  • FIGURE 26 ASIA PACIFIC: CANCER PREVALENCE, 2012–2020
  • FIGURE 27 ASIA PACIFIC: THERANOSTICS MARKET SNAPSHOT (2022)
  • FIGURE 28 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN THERANOSTICS MARKET
  • FIGURE 29 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS, 2020–2022
  • FIGURE 30 ADVANCED ACCELERATOR APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2022
  • FIGURE 31 COMPANY EVALUATION MATRIX, 2022
  • FIGURE 32 START-UP/SME EVALUATION MATRIX, 2022
  • FIGURE 33 BAYER AG: COMPANY SNAPSHOT (2022)
  • FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
  • FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
  • FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2022)
  • FIGURE 37 PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022)
  • FIGURE 38 CANON INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 39 LANTHEUS: COMPANY SNAPSHOT (2022)
  • FIGURE 40 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2022)

The study involved four major activities in estimating the current size of the theranostics market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial theranostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as OEMs, CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the theranostics market. The primary sources from the demand side include medical CDMOs, oncologists, doctors, radiologists, technicians, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Theranostics Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the theranostics market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insigh ts gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

  • Generating a list of major global players operating in the theranostics market.
  • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/category)
  • Revenue mapping of major players to cover a major share of the global market share, as of 2022
  • Extrapolating the global value of the theranostics market industry

Theranostics Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global theranostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the market was validated using top-down and bottom-up approaches.

Market Definition

Theranostics is a term used for diagnosis and therapy. Theranostics can be broadly defined as a combination of molecularly targeted imaging and therapy, whereas imaging helps to gain information regarding presence of targeted moleculaes on cell surface and therapy progression. Radiotheranostics involves the use of radionuclide/radiopharmaceutical that delivers targeted radiation to kill the cancerous cells and imaging modality such as positron emission tomography (PET) is used to locate the cancer.  FDA approved theranostics procedures are performed for different applications such as prostate cancer, neuroendocrine tumor, etc. These procedures are mainly performed in hospitals, cancer care centers, and  theranostics centers.

Key Stakeholders

  • Senior Management
  • End Users
  • R&D Department
  • Finance/Procurement Department

Objectives of the Study

  • To define, describe, and forecast the size of theranostics market based on product, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth potential of the global market (drivers, restraints, opportunities, challenges, and trends)  
  • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market.   
  • To analyze key growth opportunities in the global market for key stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments and/or subsegments with respect to three major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), and Rest of the World (Latin America and Middle East and Africa).
  • To profile the key players in the market and comprehensively analyze their market shares and core competencies.
  • To track and analyze the competitive developments undertaken in the global market, such as product launches; agreements; expansions; and mergers & acquisitions.

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global theranostics market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Geographic Analysis

  • Further breakdown of the Rest of Europe theranostics market into Italy, Spain Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
  • Further breakdown of the Rest of Asia Pacific theranostics market into Australia, South Korea, Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Theranostics Market

DMCA.com Protection Status